Neurol. pro Praxi, 2002; 1: 41-45

Terapie dysfunkcí močových cest u pacientů s roztroušenou sklerózou

MUDr. Jan Krhut1, MUDr. Karel Mainer, Ph.D., MUDr. Olga Zapletalová2
1 Urologické oddělení FNsP Ostrava
2 Neurologická klinika FNsP Ostrava-Poruba

Keywords: demyelinizace, urgence, detruzoro-sfinkterická dyssynergie, farmakoterapie, neuromodulace.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krhut J, Mainer K, Zapletalová O. Terapie dysfunkcí močových cest u pacientů s roztroušenou sklerózou. Neurol. praxi. 2002;3(1):41-45.

Roztroušená skleróza je systémové autoimunitní onemocnění postihující bílou hmotu mozku a míchy. Dochází k demyelinizaci nervových vláken a axonální ztrátě zejména v oblasti periventrikulární, v mozkovém kmeni, mozečku a postranních a zadních provazcích míchy. Ve velkém procentu případů patří do obrazu onemocnění též symptomatologie urologická ve smyslu mikčních potíží (vysoká frekvence močení, urgence, urgentní inkontinence, projevy detruzoro-sfinkterické dyssynergie), ale i závažného poškození horních močových cest. Proto je urologická terapie zaměřena jednak na zlepšení kontinence, resp. komfortu mikce a tím i kvality života, ale také na důslednou protekci horních cest močových. Autoři shrnují současné konzervativní i operační možnosti terapie mikčních symptomů s důrazem na komplexnost a individualizaci léčby.

Urologické oddělení FNsP Ostrava-Poruba

Neurologická klinika FNsP Ostrava-Poruba

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder. Urology 1997; 50 (Suppl. 6A): 90. Go to original source... Go to PubMed...
    2. Bates CP, Bradley WE, Glen E, Grifiths DJ, Melchior H, Rowan D, Sterling A, Zinner NR, Hald T. The Standadisation of terminology of lower urinary tract function. J Urol 1979; 121: 551. Go to original source... Go to PubMed...
    3. Betts ChD, D´Mellow MT, Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 1993; 56: 245. Go to original source... Go to PubMed...
    4. Blaivas JG, Bhimani G, Labib KB. Vesicourethral dysfunction in multiple sclerosis. J Urol 1979; 122: 342. Go to original source... Go to PubMed...
    5. Blaivas JG, Labib KB, Michalik SJ, Zayed AAH. Cystometric response to propantheline in detrusor hyperreflexia: therapeutic implications. J Urol 1980; 124: 259. Go to original source... Go to PubMed...
    6. Brendler CB, Radebaugh LC, Mohler JL. Topical oxybutinin chloride for relaxation of dysfunctional bladders. J Urol 1989; 141: 1350. Go to original source... Go to PubMed...
    7. Castleden CM, Duffin HM, Briggs RS, Ogden BM. Clinical and urodynamic effect of efphedrine in elderly incontinent patients. J Urol 1982; 128: 1250. Go to original source... Go to PubMed...
    8. Castleden CM, Morgan B. The effect of beta-adrenoceptor agonists on urinary incontinence in the elderly. Brit J Clin Pharm 1980; 10: 619. Go to original source... Go to PubMed...
    9. Cespedes RD, Cross CA, McGuire E. Modified Ingelman-Sundberg bladder denervation procedure for intractable urge incontinence. J Urol 1996; 156: 1744. Go to original source... Go to PubMed...
    10. Collas D, Malone-Lee JG. The pharmacocinetic properties of rectal oxybutinini: A possible alternative to intravesical administration. Neurourol Urodyn 1997; 16: 346.
    11. Delaere KPJ, Branje JPA. Rectal administraion of oxybutinin in the treatment of detrusor instability, 28-th Annual Meeting of ICS, Yerusalem, 1998.
    12. Dykstra D, Sidi A, Anderson L. The effect of nefedipine on cystoscopy-induced autonomic hyperreflexia in patients with high spinal cord injuries. J Urol 1987; 138: 1155. Go to original source... Go to PubMed...
    13. Giannantoni A, Scivoletto G, Di Stasi SM. Urological dysfunctions and upper urinary tract involvement in multiple sclerosis patients. Neurourol Urodyn 1998; 2: 89. Go to original source...
    14. Haslam J. Treating urinary incontinence using biofeedback and neuromuscular stimulation. Journal of Community Nursing 1998; 12: 28.
    15. Hanuš T. Intermitentní katetrizace močového měchýře. Čas Lék Čes 1983; 122: 1135.
    16. Havrdová E. Roztroušená skleróza mozkomíšní. In: Havrdová E. et al. Neuroimunologie. Maxdorf Jessenius, Praha 2001.
    17. Hohenfellner M, Thüroff JW, Schürmann K, Schultz-Lampel D, Schmidt RA, Tanagho EA. Sakrale Deafferentation und Implantation eines Blasenschrittmachers. In: Hohenfellner R. Ausgewählte urologische OP-Techniken. Georg Thieme Verlag Stuttgart-New York, 1994.
    18. Kiesswetter H, Schober W. Lioresal in the treatment of neurogenic bladder dysfunction. Urol Int 1975; 30: 63. Go to original source... Go to PubMed...
    19. Krhut J, Mainer K. Laser v terapii urgentní inkontinence. Pracovní konference SUS a ČUS, Vysoké Tatry, 2000.
    20. Krhut J, Mainer K. Vyšetření introitální sonografií u žen s genuinní stresovou inkontinencí léčených uretrosuspensí fasciální smyčkou. Česká urologie 2000; 4: 23.
    21. Lapides J, Diokno AC, Silber SJ, Lowe BS. Clean intermittent self-catheterization in the treatment of urinary tract disease. J Urol 1972; 107: 458. Go to original source... Go to PubMed...
    22. Lochman P, Fait T. Laser v léčbě urgentní inkontinence. Praktická urogynekologie VIII., Mělník 1999.
    23. Madersbacher H, Kiss G, Mair D. Wertigkeit der peripheren Elektrostimulation bei neurogener Blasenentleerungsstörung. Urologe (B) 1996; 36: 172.
    24. Madersbacher H, Knoll M. Intravesical application of oxybutinin: Mode of action in controlling detrusor hyperreflexia. Eur Urol 1995; 28: 340. Go to original source... Go to PubMed...
    25. Marras E, Ridolfi L, Lace R, Bianchi M. Intravesical oxybutinin hydrochloride in the managament of neurogenic bladder in paediatric age. Urodynamica 1993; 3: 93.
    26. Massad CA, Kogan BA, Trigo-Rocha FE. The pharmacokinetics of intravesical and oral oxybutinin chloride. J Urol 1992; 148: 595. Go to original source... Go to PubMed...
    27. Mayo ME, Chetner P. Lower urinary tract dysfunction in multiple sclerosis. Urology 1992; 39: 67. Go to original source... Go to PubMed...
    28. Mitrovič M, Džinič M. Laser u medicini, Medicinska knjiga Beograd-Zagreb, 1983.
    29. O´Flynn KJ, Thomas DG. Intravesical instillation of oxybutinin hydrochloride for detrusor hyperreflexia. Brit J Urol 1993; 72: 566. Go to original source... Go to PubMed...
    30. Schapiro RT. Symptom management in multiple sclerosis. Ann Neurol 1994; 36: 123. Go to original source... Go to PubMed...
    31. Schultz-Lampel D, Thüroff JW. Dranginkontinenz. In Hertle L, Pohl J. Urologische Therapie. Urban & Schwarzenberg München-Wien-Baltimore, 1993.
    32. Schultz-Lampel D, Thüroff JW. Neurogene Systemerkrankungen - Ursachen und Auswirkungen auf die Blasenfunktion. In: Stöhrer M, Madersbacher H, Palmtag H: Neurogene Blasenfunktionsstörung, neurogene Sexualstörung. Springer Berlin-Heidelberg-NewYork, 1997. Go to original source...
    33. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-Atoxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 1996; 155: 1023. Go to original source... Go to PubMed...
    34. Stöhrer M, Burgdörfer H, Goepel M. Der intermittierende Katheterismus. In: Stöhrer M, Madersbacher H, Palmtag H. Neurogene Blasenfunktionsstörung, neurogene Sexualstörung. Springer Berlin-Heidelberg-NewYork, 1997. Go to original source...
    35. Stöhrer M. Neurogene Blasenentleerungsstörungen. In: Jocham D, Miller K. Praxis der Urologie. Thieme Stuttgart - New York, 1994.
    36. Stöhrer M, Schurch B, Kramer G, Schmidt D, Gaul D, Grosse J, Hauri D. Detrusor injections of botulinum-A-toxin for detrusor hyperreflexia. BJU International 2000; 86, suppl. 3: 134.
    37. Thüroff J, Bunke B, Ebner A, et al. Randomized double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: Oxybutynin vs. propantheline vs. placebo. J Urol 1991; 145: 813. Go to original source... Go to PubMed...
    38. Tim R, Massey JM. Botulinum toxin therapy for neurologic disorders. Postgraduate Medicine 1992; 91: 327. Go to original source... Go to PubMed...
    39. Truss MC, Stief CHG, Uckert S. A possible alternative to anticholinergics in the treatment of urgency and urge incontinence: from banch to bedside. Eur Urol 1998; 33 (suppl 1): 9. Go to PubMed...
    40. Vereecken RL, Van Poppel J, Boeckx G, Leruitte A. Long-term alpha-adreergic blocking therapy in detrusor urethra dyssynergia. Eur Urol 1983; 9: 167. Go to original source... Go to PubMed...
    41. Wheeler JS, Walter JS, Zaszczurynski PJ. Bladder inhibition by penile nerve stimulation in spinal cord injury patients. J Urol 1992; 147: 100. Go to original source... Go to PubMed...
    42. Wistuba S, Roth S. Nachsorge nach Harnableitungsoperationen. In Hertle L, Pohl J: Urologische Therapie. Urban & Schwarzenberg München-Wien-Baltimore, 1993.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.